MiR-199b-5p targets HER2 in breast cancer cells

被引:72
作者
Fang, Chen [1 ]
Zhao, Yu [2 ]
Guo, Baoyu [1 ]
机构
[1] Second Mil Med Univ, Dept Biochem Pharm, Sch Pharm, Shanghai 200433, Peoples R China
[2] Shanghai Jiao Tong Univ, Sch Med, Shanghai Key Lab Gastr Neoplasms, Dept Surg,Shanghai Inst Digest Surg,Ruijin Hosp, Shanghai 200025, Peoples R China
基金
中国国家自然科学基金;
关键词
HER2; microRNA; miR-199b-5p; BREAST CANCER; LAPATINIB RESISTANCE; EXPRESSION; MICRORNA; RECEPTOR; ERBB2; ACTIVATION; PROTEIN; METASTASIS; INHIBITOR; MECHANISM;
D O I
10.1002/jcb.24487
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
HER2 (ErbB2) has been reported to be overexpressed in 2030% of breast cancer and confers poor survival because of high proliferation and metastasis rates. MicroRNAs are small noncoding RNAs that are responsible for the post-transcriptional regulation of target genes. We found miR-199b-5p inhibited HER2 expression by direct targeting its 3-untranslated region (3UTR) in breast cancer cells. In addition, miR-199b-5p inhibited HER2 downstream signaling by ERK1/2 and AKT pathways in breast cancer cells. Besides, transwell migration, wound healing, and clonogenicity were obviously inhibited by overexpression of miR-199b-5p in HER2-positive breast cancer cells. We also found that miR-199b-5p could enhance the suppression of trastuzumab on cell migration and clonogenicity. These results suggest that miR-199b-5p may have the potential to be a novel important alternative therapeutic target for HER2-positive breast cancer. J. Cell. Biochem. 114: 14571463, 2013. (c) 2013 Wiley Periodicals, Inc.
引用
收藏
页码:1457 / 1463
页数:7
相关论文
共 50 条
  • [21] LMO4 mediates trastuzumab resistance in HER2 positive breast cancer cells
    Ding, Keshuo
    Wu, Zhengsheng
    Li, Xiaocan
    Sheng, Youjing
    Wang, Xiaonan
    Tan, Sheng
    AMERICAN JOURNAL OF CANCER RESEARCH, 2018, 8 (04): : 594 - 609
  • [22] Expression and change of miR-199b-5p, s HLA-G in thyroid carcinoma
    Tan, Beibei
    Guo, Jinglan
    Wang, Li
    Wang, Lisha
    Gan, Xilun
    Chen, Boxun
    EXPERIMENTAL AND MOLECULAR PATHOLOGY, 2021, 120
  • [23] The Up-Regulation of miR-199b-5p in Erythroid Differentiation Is Associated with GATA-1 and NF-E2
    Li, Yuxia
    Bai, Hua
    Zhang, Zhongzu
    Li, Weihua
    Dong, Lei
    Wei, Xueju
    Ma, Yanni
    Zhang, Junwu
    Yu, Jia
    Sun, Guotao
    Wang, Fang
    MOLECULES AND CELLS, 2014, 37 (03) : 213 - 219
  • [24] The mir-199b-5p encapsulated in adipocyte-derived exosomes mediates radioresistance of colorectal cancer cells by targeting JAG1
    Lv, Xiaoli
    Li, Zhenyan
    Dai, Yunpeng
    Xiao, Yuji
    Shen, Fangrong
    Wang, Jian
    Cao, Jianping
    Wang, Lili
    Peng, Qiliang
    Jiao, Yang
    HELIYON, 2024, 10 (02)
  • [25] Involvement of the Dysregulation of miR-23b-3p, miR-195-5p, miR-656-5p, and miR-340-5p in Trastuzumab Resistance of HER2-Positive Breast Cancer Cells and System Biology Approach to Predict Their Targets Involved in Resistance
    Rezaei, Zohreh
    Sebzari, Ahmadreza
    Kordi-Tamandani, Dor Mohammad
    Dastjerdi, Kazem
    DNA AND CELL BIOLOGY, 2019, 38 (02) : 184 - 192
  • [26] Evaluation of the Role of p95 HER2 Isoform in Trastuzumab Efficacy in Metastatic Breast Cancer
    Rigakos, Georgios
    Razis, Evangelia
    Koliou, Georgia-Angeliki
    Oikonomopoulos, Georgios
    Tsolaki, Eleftheria
    Sperinde, Jeff
    Chrisafi, Sofia
    Zarkavelis, George
    Pazarli, Elissavet
    Batistatou, Anna
    Kourea, Helen P.
    Papakostas, Pavlos
    Bafaloukos, Dimitrios
    Asimakopoulou, Natalia, I
    Res, Eleni
    Kotsakis, Athanasios
    Pectasides, Dimitrios
    Koutras, Angelos
    Christodoulou, Christos
    Fountzilas, George
    ANTICANCER RESEARCH, 2021, 41 (04) : 1793 - 1802
  • [27] miR-135b-5p enhances doxorubicin-sensitivity of breast cancer cells through targeting anterior gradient 2
    Zhang, Ying
    Xia, Fan
    Zhang, Fan
    Cui, Yingying
    Wang, Qingling
    Liu, Hui
    Wu, Yongping
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2019, 38 (1)
  • [28] Disulfiram targets cancer stem-like properties and the HER2/Akt signaling pathway in HER2-positive breast cancer
    Kim, Ji Young
    Cho, Youngkwan
    Oh, Eunhye
    Lee, Nahyun
    An, Hyunsook
    Sung, Daeil
    Cho, Tae-Min
    Seo, Jae Hong
    CANCER LETTERS, 2016, 379 (01) : 39 - 48
  • [29] Targeted Delivery of MicroRNA125a-5p by Engineered Lipid Nanoparticles for the Treatment of HER2 Positive Metastatic Breast Cancer
    Hayward, Stephen L.
    Francis, David M.
    Kholmatov, Parviz
    Kidambi, Srivatsan
    JOURNAL OF BIOMEDICAL NANOTECHNOLOGY, 2016, 12 (03) : 554 - 568
  • [30] HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial
    Fehm, Tanja
    Mueller, Volkmar
    Aktas, Bahriye
    Janni, Wolfgang
    Schneeweiss, Andreas
    Stickeler, Elmar
    Lattrich, Claus
    Loehberg, Christian R.
    Solomayer, Erich
    Rack, Brigitte
    Riethdorf, Sabine
    Klein, Christoph
    Schindlbeck, Christian
    Brocker, Kerstin
    Kasimir-Bauer, Sabine
    Wallwiener, Diethelm
    Pantel, Klaus
    BREAST CANCER RESEARCH AND TREATMENT, 2010, 124 (02) : 403 - 412